The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents

Monika Scheer1 · Christian Vokuhl2 · Sebastian Bauer3 · Jörg Fuchs4 · Steffan Loff5 · Beate Timmermann6 · Marc Münter7 · Anton George Henssen1 · Bernada Kazanowska8 · Felix Niggli9 · Ruth Ladenstein10 · Gustaf Ljungman11 · Ewa Koscielniak12,13 · Thomas Klingebiel14 on behalf of the European Cooperative Weichteilsarkom Studiengruppe [CWS]

Received: 5 December 2020 / Accepted: 22 March 2021 / Published online: 17 July 2021 © The Author(s) 2021

Abstract
Background The benefit of adjuvant therapy in synovial sarcoma (SS) treatment is under debate. Long-term follow-up data are missing.
Methods SS patients treated in the consecutive trials CWS-81, CWS-86, CWS-91, CWS-96, CWS-2002-P, and the SoTiSaR-registry till 2013 were analyzed.
Results Median age of 185 patients was 13.9 years (0.1–56)—with median follow-up of 7.4 years for 163 survivors. Most tumors (76%) were located in extremities. Size was < 3 cm in 58 (31%), 3–5 cm in 59 (32%), 5–10 cm in 42 (23%), and > 10 cm in 13 (7%) (13 missing). In 84 (45%) tumors, first excision was complete (R0 corresponding to IRS-I-group) and in 101 (55%) marginal (R1 corresponding to IRS-II-group). In a subsequent surgical intervention during chemotherapy, R0-status was accomplished in 23 additional IRS-II-group patients with secondary surgery. Radiotherapy was administered to 135 (73%), thereof 62 with R0-status and 67 R1-status (6 missing information). Adjuvant chemotherapy was administered to all but six patients. 5-year event-free (EFS) and overall survival (OS) was 82.9% ± 5.7 (95%CI) and 92.5% ± 3.9. Local and metastatic relapse-free survival was 91.3% ± 4.3 and 92.3% ± 4.1 at 5 years, respectively. In the multivariate analysis, tumor size and no chemotherapy were independently associated with EFS. Size and site were associated with OS. In a detailed analysis of local and metastatic events, tumor size was associated with an independent risk for developing metastases. No independent factor for suffering local recurrence could be identified.
Discussion Omission of chemotherapy in a non-stratified way seems not justified. Size governs survival due to high linear association with risk of suffering metastatic recurrence in a granular classification.

Keywords Synovial sarcoma · Soft-tissue sarcoma · Pediatric sarcoma · Adjuvant therapies · Chemotherapy · Radiotherapy

Introduction
Soft-tissue sarcomas represent nearly 8% of childhood malignancies. Synovial sarcoma (SS) is the most common non-rhabdomyosarcoma soft-tissue sarcoma (Goldblum 2014; Pizzo and Poplack 2011), characterized by the specific translocation t(X:18). It typically affects the extremities of adolescents, as well as of young adults. The main age range is between 10 and 40 years. Pathological features are identical in all age groups (Goldblum 2014; Pizzo and Poplack 2011).

Whereas pediatric oncologists assumed that chemotherapy might play an important role, and administered adjuvant chemotherapy regardless of risk factors (Ferrari et al. 1999, 2004; Schmidt et al. 1991; Ladenstein et al. 1993; Pappo et al. 1994; Okcu et al. 2001, 2003), adult oncologists considered SS as a tumor with uncertain chemosensitivity (Frustraci et al. 2001; Sarcoma Meta-analysis Collaboration 1997; Brodsky et al. 1992; Bergh et al. 1999; Lewis et al. 2000; Spillane et al. 2000; Trassard et al. 2001). Pediatric trials reported very satisfactory results with up to 75–80% of
survival rates (Ferrari et al. 1999, 2004; Schmidt et al. 1991; Ladenstein et al. 1993; Pappo et al. 1994; Okcu et al. 2001, 2003), better than those in adult series (Ferrari et al. 2004; Frustaci et al. 2001; Sarcoma Meta-analysis Collaboration 1997; Brodsky et al. 1992; Bergh et al. 1999; Lewis et al. 2000; Spillane et al. 2000; Trassard et al. 2001)—evolving the discussion if age per se is a risk factor (Hayes-Jordan et al. 2000) or if this is caused by the differing treatment approaches (Baldi et al. 2019; Tarkan et al. 2014; Italiano et al. 2009; Outani et al. 2019). Currently, treatment strategies converge towards more common strategies. However, especially for adolescents, still existing controversies cause discussions. Apart from systemic treatment, there is also disagreement about the required local aggressiveness. While, some reported resections with free margins to be crucial, especially pediatric series reported no differences in resections with positive margins (Orbach et al. 2011). Summarized, adjuvant therapies in grossly resected SS are still a matter of debates.

**Patients and methods**

Patients treated 1980–2013 in the trials CWS-81 (Koscielniak et al. 1992), CWS-86 (Koscielniak et al. 1999), CWS-91 (Dantonello et al. 2009), CWS-96 (Modritz et al. 2005), CWS-2002-P (Koscielniak et al. 2013), and the registry CWS-SoTiSaR were eligible if (i) diagnosis was proven by central reference review (including molecular confirmation since 2000), (ii) no evidence of metastases existed, (iii) no previous treatment was performed, and (iv) the tumor was initially grossly resected.

All CWS-trials were prospective and approved by appropriate ethics committees. Written informed consent was obtained from patients, guardians/parents, or both (Dantonello et al. 2008, 2009). Clinical information, treatment data, and outcome were available for all. Some had been included in previous analysis (pathological slides were reviewed for the purposes of those studies) (Stegmaier et al. 2017; Scheer et al. 2016).

Disease was staged according to the clinical tumor-node-metastases (TNM) classification (Harmer et al. 1970) which confines T1-tumors to the organ/tissue of origin, while T2-lesions invade contiguous structures and regional node involvement as N0 or N1, based on histological or clinical/radiological assessments (Baldi et al. 2019). Originally developed for rhabdomyosarcoma, but extended to other chemotherapy-sensitive pediatric STS, the Intergroup Rhabdomyosarcoma Study (IRS) post-surgical grouping system (Maurer et al. 1988) categorizes patients based on the extent of residual tumor after first surgery: primary completely excised tumors with negative microscopic margins (R0) correspond to IRS-I; primary microscopically resected tumors with microscopic residual disease (R1); IRS-II; macroscopic residual disease after incomplete resection or biopsy (R2); IRS-III; and metastases at onset: IRS-IV (Maurer et al. 1988).

Generally, a primary excision was attempted if complete and non-mutilating resection was considered feasible. Any re-surgery performed up to 4 weeks after biopsy/inadequate primary resection before any other treatment was defined as primary re-excision and considered in the IRS-system. The consecutive CWS-protocols recommended chemotherapy in all patients. The regimens were VACA (vincristine, actinomycin-D, cyclophosphamide, adriamycin) in CWS-81 (Koscielniak et al. 1992), and VAIA, which incorporates ifosfamide instead of cyclophosphamide, in CWS-86 (Koscielniak et al. 1999) and in all protocols including and following CWS-96 (Modritz et al. 2005; Koscielniak et al. 2013). The CWS-91-trial investigated therapy intensification with etoposide (EVAIA) (Dantonello et al. 2009). Since the CWS-96-protocol, the VAIA-regimen is used (Modritz et al. 2005; Koscielniak et al. 2013).

Radiotherapy was recommended for all except for IRS-I (primary R0) patients, where it was only recommended in CWS-86 and CWS-91. According to the respective CWS-protocol radiotherapy at doses of 32–54.4 Gy (when accelerated hyperfractionated) and 40–50 Gy if conventional fractionated dependent on response to chemotherapy and resection status was to be administered in analogy to recommendations for patients with rhabdomyosarcoma (Koscielniak et al. 1992, 1994, 1999; Dantonello et al. 2009, 2013). The CWS-91-trial investigated therapy intensification with etoposide (EVAIA) (Dantonello et al. 2009). Since the CWS-96-protocol, the VAIA-regimen is used (Modritz et al. 2005; Koscielniak et al. 2013).

Best surgery was defined as the best surgical result at the end of treatment independent from the number of procedures. It was categorized as the presence of microscopic [R1] residual tumor or as resection with free margins [R0].

**Statistical methods**

Statistics were calculated using SPSS® 24 (IBM SPSS, Armonk, NY, USA). Comparison of distribution was performed with the χ²-test. Event-free survival [EFS] and overall survival [OS] were calculated using the Kaplan–Meier estimator (Kaplan andMeier 1958). For OS, time from diagnosis to death or last follow-up was calculated, for EFS time from diagnosis to first relapse/progression, death, or last follow-up. The local relapse-free survival [LRFS] was calculated from diagnosis to local (included combined) relapse. Metastases-free survival [MFS] was calculated from diagnosis to the onset of distant metastases. Patients who died of their tumor after distant failure, prior to local progression/relapse, were censored at the time of death in the analysis of LRFS. Confidence intervals [CI] for the Kaplan–Meier estimator were computed using Greenwoods Formula (Greenwood 1926) and are stated at the 95% level. For comparison
of EFS, OS, LRFS, and MFS levels, the log-rank test was used. The Cox proportional hazard regression model was used to assess the effects of each potential prognostic variable on survival rates (Orbach et al. 2011). A stepwise variable selection procedure (combination of forward and backward selection techniques) was applied to the covariates with a p value of at least 0.05 in EFS, OS, LRFS, or MFS at the univariable analysis. Hazard ratios (HRs) with 95% CIs, calculated according to the Wald method, are reported for the evaluated variables.

Results

Characteristics

Among 330 patients with localized SS, 185 had undergone initial gross resection, thereof 84 with primary free margins IRS-I/(R0) and 101 with primary positive margins IRS-II/ (R1). Gender distribution was balanced (Table 1). Median age was 13.9 years (first month of life–56.8). Localization of the primary tumor was: extremities 140 (76%), head–neck 10 (5%), shoulder or hip 20 (11%), and trunk 12 (8%). Local invasiveness (T2) was reported in 49 (26%) and size > 5 cm in 59 (32%). Six patients (3%) had nodal involvement.

Treatment

Chemotherapy was given to all but six: 141 (76%) received the VAIA, 1 the EVAIA, and 30 (16%) the VACA regimen.

In the IRS-II/(R1) group, 23 of 101 patients underwent second surgical intervention only after the start of chemotherapy to obtain a tumor cell-free primary site. Therefore, in total, 107 (58%) achieved a R0-status as best surgical result at any time.

Radiotherapy was administered to 135 (73%): 45 out of 84 (54%) IRS-I/(R0)-patients and 89 out of the 101 (88%) IRS-II/(R1) (detailed presentation in Fig. 1). The documented total dose ranged from 32 to 60 Gy, while the majority received <50 Gy.

Outcome

At last follow-up, 163/185 (88%) were alive. Median follow-up for survivors was 7.4 years (0.7–31.1). Twenty patients died of disease, two of treatment toxicity (according to the documentations of the participating centers: 1. “cardiogenic shock, cachexia” in first-line therapy while receiving the VACA regimen, 2. “liver failure, organ failure” in relapse chemotherapy).

3-, 5-, and 10-year EFS was 87.9% ± 4.7, 82.9% ± 5.7 and 75.2% ± 7.4. 3-, 5- and 10-year OS was 95.0% ± 3.1, 92.5% ± 3.9 and 84.6% ± 6.7, respectively.

Pattern of relapse

39 patients developed recurrences, 16 local, 14 metastatic, 4 at local and distant sites combined. For 5 patients, type of relapse was not specified (Table 2). 3-, 5-, and 10-year LRFS and MFS were 93.9% ± 3.5, 91.3% ± 4.3, 86.9% ± 5.9 and 94.9% ± 3.3, 92.3% ± 4.1, 87.7% ± 6.1, respectively. Median time to local failure was 2.5 years. The latest local recurrences were documented at 7.7, 8.6, 11.5, and 16.0 years, respectively. Median time to distant failure without involvement of the primary region was 2.7 years. The latest occurrence of metastases was documented at 4.0, 5.8, 6.2, and 8.6 years.

The proportion of metastatic recurrences increased with larger tumor size. The rate of local relapses did not differ with size (Table 3).

Factors for survival

In the univariate analysis, factors associated with adverse EFS were large tumor size and no application of chemotherapy (Table 1, Fig. 1). Factors associated with adverse OS were tumor location at the head–neck, large tumor size, invasiveness (T2-status), and no application of chemotherapy. Survival was not associated with surgical margins.

In the Cox regression analysis, large tumor size and no application of chemotherapy were associated with adverse EFS. Large tumors and tumors localized at head–neck were associated with adverse OS (Table 4).

Factors for local and metastatic events

In the detailed evaluation of local and metastatic events, size and application of chemotherapy correlated with LRFS. Size, invasiveness (T-status) and chemotherapy correlated with MFS. In the Cox regression analysis, no independent factors for LRFS were identified. Size was associated with independent risk for MFS.

Chemotherapy

When we analyzed patients treated with cyclophosphamide-based regimens (VACA) versus those treated with ifosfamide-based regimen (VAIA) versus those without chemotherapy, patients treated with the VAIA or the VACA scheme did not show different outcomes (5-year EFS and OS were 83.1% and 86.0% for VACA and 85.7% and 95.4% for VAIA, respectively), whereas 6 patients without chemotherapy did significantly worse (5-year EFS and OS were 22.2% and 62.5%; p < 0.001).

Among those six patients treated with local therapy alone 2 were reported to be in ongoing complete first remission at 12.4 years (primary tumor size < 3 cm) and
Table 1  Univariate analysis of 185 IRS-I and IRS-II patients

| Studies          | N (%) | 5 yr EFS (95% CI) | p value | 5 yr OS (95% CI) | p value | 5 yr LRFS (95% CI) | p value | 5 yr MFS (95% CI) | p value |
|------------------|-------|-------------------|---------|------------------|---------|--------------------|---------|--------------------|---------|
| CWS 81           | 17 (9)| 88.2 ± 15.3       | 0.862   | 87.8 ± 15.9      | 0.819   | 100%               | 0.912   | 93.8 ± 12.0        | 0.843   |
| CWS-86           | 27 (15)| 81.5 ± 14.7       | 92.6 ± 9.8 | 88.6 ± 12.2       | 88.6 ± 12.2 |
| CWS-91           | 18 (10)| 76.6 ± 20.2       | 88.2 ± 15.3 | 87.7 ± 16.1       | 88.1 ± 15.5 |
| CWS-96           | 59 (32)| 85.9 ± 9.0        | 92.5 ± 7.1 | 91.3 ± 7.3        | 92.4 ± 7.3 |
| CWS 2002P        | 39 (21)| 83.8 ± 12.0       | 97.3 ± 5.3 | 91.9 ± 8.8        | 94.7 ± 7.3 |
| SoTiSaR          | 25 (14)| 75.1 ± 20.6       | 91.8 ± 10.8 | 91.3 ± 11.6       | 95.7 ± 8.4 |
| Gender           |       |                   |         |                  |         |                    |         |                    |         |
| Female           | 94 (51)| 87.9 ± 6.7        | 0.295   | 94.4 ± 4.7       | 0.133   | 94.3 ± 4.9         | 0.335   | 95.6 ± 4.3         | 0.254   |
| Male             | 91 (49)| 77.6 ± 9.0        |         | 90.4 ± 6.3       |         | 88.0 ± 7.1         |         | 88.7 ± 7.1         |         |
| Age (years)      |       |                   |         |                  |         |                    |         |                    |         |
| ≤ 10             | 36 (19)| 88.6 ± 10.6       | 0.872   | 94.3 ± 7.6       | 0.926   | 91.2 ± 9.6         | 0.258   | 96.4 ± 6.7         | 0.053   |
| 10–21            | 133 (72)| 82.5 ± 6.7        | 92.8 ± 4.5 | 90.3 ± 5.3        | 93.5 ± 4.3 |
| ≥ 21             | 16 (9) | 73.3 ± 22.3       | 85.6 ± 18.6 | 100%              |         | 73.3 ± 22.3       |         |                    |         |
| Site             |       |                   |         |                  |         |                    |         |                    |         |
| Extremities      | 140 (76)| 84.1 ± 6.3       | 0.502   | 94.6 ± 3.9       | 0.017   | 92.1 ± 4.7         | 0.799   | 93.0 ± 4.3         | 0.431   |
| Head–neck        | 10 (5) | 90.0 ± 18.6       | 100%    | 100%             | 100%    | 100%               |         |                    |         |
| Shoulder or hip  | 20 (11)| 85.0 ± 15.7       | 84.4 ± 16.3 | 90.0 ± 13.1       | 94.7 ± 10.0 |
| Trunk            | 15 (8) | 66.7 ± 23.9       | 80.0 ± 20.2 | 80.0 ± 20.2       | 76.9 ± 22.9 |
| Size             |       |                   |         |                  |         |                    |         |                    |         |
| < 3 cm           | 58 (31)| 89.8 ± 8.6        | 0.011   | 100%             | <0.001  | 89.8 ± 8.6         | 0.037   | 100%               | 0.002   |
| 3–5 cm           | 59 (32)| 91.2 ± 7.3        | 98.3 ± 3.3 | 98.2 ± 3.5        | 94.5 ± 6.1 |
| 5–10 cm          | 42 (23)| 75.4 ± 13.3       | 84.9 ± 11.2 | 84.8 ± 11.2       | 89.2 ± 10.0 |
| > 10 cm          | 13 (7) | 53.8 ± 27.0       | 69.2 ± 25.1 | 84.6 ± 10.0       | 65.8 ± 27.6 |
| No information   | 13 (7) |                   |         |                  |         |                    |         |                    |         |
| Size (5 cm)      |       |                   |         |                  |         |                    |         |                    |         |
| ≤ 5 cm           | 119 (64)| 90.8 ± 5.5        | 0.004   | 99.2 ± 1.6       | <0.001  | 94.3 ± 4.5         | 0.048   | 97.2 ± 1.6         | 0.005   |
| > 5 cm           | 59 (32)| 70.6 ± 11.8       | 82.5 ± 9.8 | 85.5 ± 9.2        | 85.2 ± 9.6 |
| No information   | 7 (4)  |                   |         |                  |         |                    |         |                    |         |
| T-status         |       |                   |         |                  |         |                    |         |                    |         |
| T1               | 130 (70)| 86.2 ± 6.1        | 0.058   | 95.2 ± 3.7       | 0.040   | 91.6 ± 4.9         | 0.609   | 94.0 ± 4.3         | 0.032   |
| T2               | 49 (26)| 73.1 ± 12.5       | 85.0 ± 10.4 | 89.4 ± 8.8       | 87.3 ± 9.6 |
| TX               | 6 (3)  |                   |         |                  |         |                    |         |                    |         |
| N-status         |       |                   |         |                  |         |                    |         |                    |         |
| N0               | 170 (92)| 82.2 ± 5.9        | 0.757   | 91.8 ± 4.3       | 0.857   | 90.5 ± 4.5         | 0.938   | 91.6 ± 4.3         | 0.725   |
| N1               | 6 (3)  | 100%              | 100%    | 100%             | 100%    |                    |         |                    |         |
| NX               | 9 (5)  |                   |         |                  |         |                    |         |                    |         |
| IRS              |       |                   |         |                  |         |                    |         |                    |         |
| IRS-I            | 84 (45)| 79.1 ± 8.8        | 0.119   | 89.9 ± 6.7       | 0.449   | 89.6 ± 6.9         | 0.459   | 89.8 ± 6.7         | 0.435   |
| IRS-II           | 101 (55)| 86.3 ± 9.6        | 94.7 ± 4.5 | 92.9 ± 5.1       | 94.5 ± 4.7 |
| Chemotherapy     |       |                   |         |                  |         |                    |         |                    |         |
| No               | 6 (3)  | 22.2 ± 37.6       | <0.001  | 62.5 ± 41.5       | 0.003   | 44.4 ± 43.5        | <0.001  | 75.0 ± 42.5        | 0.001   |
| VACA             | 30 (16)| 83.1 ± 13.5       | 86.0 ± 12.7 | 92.7 ± 9.8       | 93.1 ± 9.2 |
| VAIA*            | 141 (76)| 85.7 ± 5.88      | 95.4 ± 3.5 | 93.3 ± 4.3       | 93.1 ± 4.3 |
| No information   |        |                   |         |                  |         |                    |         |                    |         |
0.7 years (size missing) after first diagnosis. One suffered local relapse at 1.8 years (primary size 5–10 cm); he is reported alive in second complete remission 10.2 years after first diagnosis. Two suffered combined relapses at 0.3 years (primary tumor size 5–10 cm) and 0.5 years (size missing); both are dead of disease 0.5 and 2.8 years after diagnosis. One patient presented with metastatic relapse 1.5 years (primary tumor size 3–5 cm) after diagnosis and was reported alive at 3.8 years.

**Radiotherapy**

Univariate analysis showed no significant correlation between radiotherapy and survival rates for the entire cohort.
The analysis of merely IRS-I/(R0)-patients revealed that 5-year EFS was 81.8 ± 11.4% for patients receiving radiotherapy and 72.2 ± 15.5% for those who did not (supplementary table 1). The application of radiotherapy was also not associated with local or metastatic relapse risk.

For IRS-II/(R1)-patients, EFS was 86.7 ± 3.7% for irradiated (n = 89) and 77.8 ± 13.9% for non-irradiated patients (n = 9), while 5-year OS was 96.3 ± 2.1% and 77.8 ± 13.9%, respectively. There was no significant association with local or metastatic recurrences (supplementary table 2).

In the subgroup of 23 IRS-II/(R1)-patients with second ary R0-resection while on chemotherapy, 6 did not receive radiotherapy. One of those 6 suffered combined relapse, whereas the 5 remaining were reported in ongoing first remission for 4.9 years (2.2–10.4). 17 did receive additional radiotherapy to the secondary R0-resection, and one suffered metastatic and one local relapse (Fig. 1, supplementary table 2).

Small tumors

In the subgroup of those 56 patients with tumors < 5 cm and resection with negative margins IRS-I/(R0), 3-year-EFS was 94.6% ± 5.9. 5-year-EFS was 90.5% ± 8.0, 10-year-EFS 79.1% ± 12.9, and the 5-year-OS was 100%. This does not differ to the results of the IRS-I/(R0)-patients. All 63 patients received chemotherapy (53 VAIA, 9 VACA) with 1 missing information. 8 suffered relapse with a median follow-up of 6.8 years (1.2–16.6), thereof 5 local, 2 metastatic, 1 unspecified. Median time to relapse was 3.2 years (1.3–16.0).

Secondary malignancies and long-term toxicities due to radiotherapy and chemotherapy

Secondary malignancy was documented in 4 patients: [(1) benign ganglieneuroma and enchondroma of the fibula, (2) melanoma in situ, left foot, (3) embryonal carcinoma of the testis, and (4) basal cell carcinoma]. All patients achieved a remission of their secondary tumor.

Information on late effects was available for 142 patients. Thereof 72 patients (51%) did not suffer any late effect. Among those 70 other patients, mainly late sequelae in the extremities was generally documented by the participating centers. Among the 70 patients in the whole, 12 were documented with renal dysfunction, 8 with neuropathy, and 2 with cardiomyopathy. 57 of those 70 patients were irradiated. In 10 irradiated patients, specifically loss of function of their extremity was documented and in 3 other irradiated patients leg length differences or growth problem of the limb.

Discussion

Whereas pediatric and adult studies mostly agree on factors influencing SS outcome (Ferrari et al. 1999, 2004; Schmidt et al. 1991; Ladenstein et al. 1993; Pappo et al. 1994; Okcu et al. 2001, 2003; Brodsky et al. 1992; Bergh et al. 1999; Lewis et al. 2000; Spillane et al. 2000; Trassard et al. 2001;
Koscielniak et al. 1992, 1999; Dantonello et al. 2009), there is no consensus on how patients should be classified to receive adjuvant therapy. In particularly, those factors essential for risk stratification in relation to chemotherapy have not yet been defined uniformly across age groups. All 185 patients analyzed here are treated in prospective trials with median follow-up of more than 7 years for survivors. We can conclude that children, adolescents, and adults with grossly resected SS treated according to CWS recommendations have an excellent prognosis with an expected 5-year and 10-year OS of 93% and 85%, respectively. Regarding first relapse, patients had a local recurrence rate of 18%, a distant metastases rate of 16%, and a combined relapse rate of both local and distant lesions of 4%. Despite this excellent outcome, patients with large and very large tumors and those without chemotherapy are at independent risk for adverse events. The evaluation of distinct event types reveals that the risk of suffering metastatic recurrence is independently and moreover linearly associated with large tumors in a granular size classification. No independent factor for local recurrence was identified.

All except for six patients received chemotherapy. This small unselected subgroup has refused chemotherapy. Multivariate analysis proves independent impact of chemotherapy. However, results might be compromised by a low number in the non-chemotherapy group and can only be interpreted in consideration with the literature. In a prior attempt, the CWS and Italian IGC have reviewed the data of grossly resected SS in 2006. The study identified a subset of low-risk patients (IRS-I, < 5 cm), for which the omission of adjuvant chemotherapy might be recommended (Brecht et al. 2006). Consequently, according to the EpSSG-recommendations 2005, those patients were treated with surgery only. Patients with tumors < 5 cm and/or resection with positive margins were recommended to have chemotherapy and radiotherapy (Ferrari et al. 2015). In the COG ARST0332 trial (NCT00346164), for newly diagnosed non-rhabdomyosarcoma soft-tissue sarcoma, starting in 2007, patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm with negative margins had not received adjuvant or further therapy. In 2017, Ferrari et al. reported results of 3-year EFS of 90% in 60 patients with median follow-up of 5.2 years. All eight events were local recurrences. All were effectively salvaged. The authors consequently conclude that adequately resected SS < 5 cm, regardless of grade can be safely treated with a surgery only approach.

In our subgroup of those 56 patients with tumors < 5 cm resected with negative margins (IRS-I/R0), 3-year EFS was 94.6% ± 5.9. This does not differ from the results without chemotherapy. In our series, 9/56 suffered relapse, thereof 5 local, 3 metastatic, 1 unspecified with median follow-up of 7.5 years. 4/9 events occurred after 5.2 years. Median
Table 4  Multivariate analysis of clinical and treatment variables for EFS, OS, LRFS and MFS

| Variables          | EFS Hazard ratio | CI (95%) lower | CI (95%) upper | p value | OS Hazard ratio | CI (95%) lower | CI (95%) upper | p value | LRFS Hazard ratio | CI (95%) lower | CI (95%) upper | p value | MFS Hazard ratio | CI (95%) lower | CI (95%) upper | p value |
|--------------------|------------------|----------------|----------------|---------|-----------------|----------------|----------------|---------|------------------|----------------|----------------|---------|-----------------|----------------|----------------|---------|
| Age (years)        |                  |                |                |         |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| ≤ 10               | 1                | 0.833          | 1              | 0.900   | 1               | 0.415          | 1              | 0.258   |
| 10–21              | 1.144            | 0.381          | 3.433          | 0.810   | 0.812           | 0.780          | 0.447          | 0.185   | 1.050            | 0.184          | 5.993          | 0.956   |
| ≥ 21               | 1.624            | 0.320          | 8.249          | 0.559   | 1.231           | 0.096          | 15.769         | 0.000   | 0.983            | 3.552          | 0.408          | 0.251   |
| Site               |                  |                |                |         |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| Extremities        | 1                | 0.148          | 1              | 0.078   | 1               | 0.825          | 1              | 0.252   |
| Head–neck          | 4.109            | 1.101          | 15.335         | 0.035   | 14.203          | 0.018          | 0.704          | 0.068   | 7.293            | 0.769          | 7.399          | 0.898   | 60.936          | 0.063          |
| Shoulder–hip       | 1.206            | 0.342          | 4.253          | 0.771   | 3.781           | 0.077          | 1.407          | 0.289   | 6.854            | 0.673          | 0.821          | 0.098   | 6.873           | 0.856          |
| Trunk              | 0.707            | 0.159          | 3.140          | 0.649   | 2.599           | 0.553          | 12.202         | 0.226   | 0.420           | 0.048          | 3.689          | 0.434   | 0.781           | 0.086          | 7.089          | 0.826   |
| Size               |                  |                |                |         |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| < 3 cm             |                  | 0.025          | 1              | 0.011   | 1               | 0.197          | 1              | 0.039   |
| 3–5 cm             | 0.698            | 0.248          | 1.959          | 0.494   | 3.203           | 0.320          | 0.256          | 0.051   | 1.281            | 0.097          | 3.393          | 0.364   | 31.627          | 0.282          |
| 5–10 cm            | 2.065            | 0.717          | 5.947          | 0.179   | 17.719          | 1.740          | 180.444        | 0.015   | 1.497           | 0.451          | 4.969          | 0.510   | 9.285           | 0.883          | 97.669         | 0.063   |
| > 10 cm            | 4.492            | 1.217          | 16.588         | 0.024   | 41.462          | 3.204          | 536.641        | 0.004   | 1.714           | 0.256          | 11.490         | 0.579   | 28.480          | 2.205          | 367.925        | 0.010   |
| T-Status           |                  |                |                |         |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| T1                 | 1                | 1              | 1              | 1       |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| T2                 | 1.242            | 0.541          | 2.852          | 0.609   | 0.988           | 0.316          | 3.091          | 0.984   | 1.448           | 0.460          | 4.555          | 0.527   | 1.084           | 0.319          | 3.686          | 0.897   |
| Chemo              |                  |                |                |         |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| VAIA*              | 1                | 0.002          | 1              | 0.183   | 1               | 0.178          | 1              | 0.238   |
| VACA               | 1.836            | 0.731          | 4.613          | 0.196   | 3.142           | 0.852          | 11.587         | 0.086   | 1.687           | 0.502          | 5.673          | 0.398   | 1.477           | 0.361          | 6.042          | 0.588   |
| No                 | 12.903           | 2.764          | 60.226         | 0.001   | 2.664           | 0.262          | 27.097         | 0.408   | 6.378           | 0.665          | 61.200         | 0.108   | 7.766           | 0.686          | 87.927         | 0.098   |
| Radio-therapy      |                  |                |                |         |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| Yes                | 1                | 1              | 1              | 1       |                 |                |                |         |                  |                |                |         |                 |                |                |         |
| No                 | 1.211            | 0.472          | 3.106          | 0.691   | 2.328           | 0.688          | 7.877          | 0.174   | 1.959           | 0.588          | 6.527          | 0.273   | 0.556           | 0.098          | 3.160          | 0.508   |

Bold values indicate statistical significance

*Thereof 1 with EVAIA
Fig. 2  EFS, OS, LRFS and MFS according to tumor size. LRFS and MFS according to patients’ age. LRFS and MFS according to chemotherapy
follow-up for the Ferrari series is merely 5.2 years. Long-term results are therefore highly anticipated. International cooperation with biological accompanying investigation would be needed to finally resolve this question.

In our subgroup of 63 patients with tumors < 5 cm and resection with positive margins (IRS-II/R1), 3-year-EFS was 93.3% ± 6.3. This does not differ from the IRS-I/(R0)-group. There is neither a difference between IRS-I/(R0) and IRS-II/(R1)-group, nor between best surgeries obtained in a second intervention during chemotherapy. However, patients with positive margins mostly received irradiation. Nevertheless, it should be underlined that the risk of metastatic relapse does not differ. Obviously, distant spread occurs before resection. Therefore, omission of chemotherapy might be an approach worth discussing in grossly resected SS < 5 cm regardless of resection margins.

There are very few evaluations that deal with the question of which systemic anti-cancer drugs specific to SS improve outcome best (Baldi et al. 2019; Riedel et al. 2018). Knowledge of effective substances mainly derives from retrospective analyses and basket trials. The patients in our series received the VACA (vincristine, adriamycin, cyclophosphamide, actinomycin-D) or the VAIA (vincristine, adriamycin, ifosfamide, actinomycin-D) regimen. In the course of history, the combination VAIA has prevailed. In the present analysis, there was no significant difference between VACA and VAIA with a slightly better outcome with VAIA. Therefore, in patients who do not tolerate ifosfamide, the use of cyclophosphamide might not compromise outcome. Interestingly, the metastasis relapse-free survival of patients > 21 years is worse than that of patients < 21 years. Even though the indication for chemotherapy in adult synovial sarcoma patients is not standardized, the chemotherapy combination commonly used consists of doxorubicin/ifosfamide. However, in this series, all patients were treated according to the respective pediatric protocol. The nonetheless poorer metastasis-free survival of patients > 21 years raises the question of biological differences in different age groups.

CWS-protocols recommend radiotherapy for all SS patients except for IRS-I/(R0), where it was only recommended in CWS-86 and CWS-91. There is no clear evidence of the role of radiotherapy in IRS-I/(R0). A favorable trend with no statistically significant difference was shown (Ferrari et al. 2004). In the CWS-Italian co-analysis (Brecht et al. 2006), no benefit was observed, irrespective of tumor size. Consequently, no radiotherapy for IRS-I/(R0)-patients is recommended regardless of size and T-status in the CWS recommendations.

In patients with initial complete macroscopic resection with positive margins (IRS-II/R1), the indication for radiotherapy is a matter of debate. Generally, it is considered as indicated. In the common analysis (Brecht et al. 2006), treatment results for IRS-II/(R1) patients were comparable to those in IRS-I/(R0). Nearly all IRS-II/(R1) patients received radiotherapy. Nevertheless, data from Orbach et al. showed similar outcome regardless of irradiation in a subset of 27 IRS-II/(R1) patients, thus suggesting that radiotherapy may not be necessary after microscopic incomplete surgery (Orbach et al. 2011). Interestingly, in our IRS-II/(R1) patients, the administration of radiotherapy was also not associated with improved survival or with reduced risk of local recurrence. In a closer look at the subgroup of those with R1-resection as best surgical result at the end of treatment and treated without radiotherapy, relapse rate did not differ from the subgroup of R0 resected SS and of those treated with radiotherapy (Fig. 1, supplementary table 2).

Interestingly, the degree of surgery also lacked its prognostic role—unlike others reported (Ferrari et al. 2004; Ladenstein et al. 1993; Pappo et al. 1994; Okcu et al. 2003; Harmer et al. 1970). The reasons that may partially explain differences might probably relate, at least in part, to the difficulty of a precise definition of IRS-II and R1 due to adequate surgical approach and adequate surgical margins. However, chemotherapy affects not only the potential spread distant micro-metastases, but also the primary or tumor cells that might have remained in the primary tumor area after gross resection. In this way, chemotherapy can also be considered as local therapy. It is a generally accepted fact that prognostic factors should not be interpreted apart from the particular study population and the therapeutic context. Beyond that, the aggressiveness of local therapy cannot be assessed correctly when considered independently of systemic therapies. To put this in more general terms, chemotherapy might reduce the required aggressiveness. Differences in the applied systemic therapies might explain the contradictory or inconsistent results (Tarkan et al. 2014; Yaser et al. 2014; Salcedo-Hernandez et al. 2013; Vining et al. 2017). However, in clinical use, this interpretation would be important in complicated local situations.

Unfortunately, grading was not available for many of the patients included during the long recruitment period. In former times, synovial sarcoma was generally considered as a high-grade tumor (Ferrari et al. 2015), whereas nowadays, tumor grade is considered to be a predictive factor (Bianchi et al. 2017; Guillou et al. 2004). Nevertheless, our group could not provide evidence for this (Stegmaier et al. 2017).

The consecutive CWS studies had general follow-up recommendations. These were not sarcoma subtype specific. There were only slight differences between the different studies. Regular routine examinations were recommended for 5 years after completion of therapy. Summarized, in the first year, regular cross-sectional imaging of the primary tumor region, preferably MRI, was recommended at 4-month intervals. In the following 2 years, at intervals of 6 months. After 3 years, intervals of 6–12 months were recommended.
Chest-X-ray or CT thorax (at least every 6 months), ultrasound abdomen/pelvis (at least every 6 months), and a bone scan (risk-adapted, once a year) were recommended in the first year. Chest X-ray was recommended at 6-month intervals in the second year, followed by annual checks until 5 years after completion of therapy. From the 6th year onwards, controls by sonography/cross-section imaging of the primary tumor region and lung imagings were recommended with frequency at the discretion of the responsible physician. Interestingly, despite the known heterogeneity of soft-tissue sarcoma and in particularly of the group of NRSTS, there are no detailed subtype-specific follow-up recommendations. In this series of grossly resected SS, median time to local failure was 2.5 years. Median time to distant failure without involvement of the primary region was 2.7 years. This result might suggest regular imaging follow-up examinations at closer intervals (e.g., 4 months) until 3 years after the end of therapy, and then an extension of the intervals. The latest local recurrences were documented at 11.5 and 16.0 years and the latest occurrence of metastases at 6.2 and 8.6 years, respectively. Annual control examinations until ~10 years after the end of therapy might seem reasonable. The possibility of a very late relapse should be known by the treating physicians. Most relapses are, however, detected due to clinical signs and symptoms and the patients should be educated to contact their oncologist immediately in case of unclear symptoms. It seems reasonable to incorporate the identified risk factors in the follow-up recommendations, e.g., patients with tumors <5 cm have a significantly lower risk of suffering metastatic recurrence (whereas 72% of patients with a SS > 10 cm suffer metastatic relapse, Table 3). In the future, it will be important to also incorporate the constantly growing knowledge of tumor biology or rather biological risk factors into the recommendations for follow-up care.

In summary, to our knowledge, this analysis represents the largest series of grossly resected SS treated in prospective risk-adapted trials so far. It adds interesting data that could be helpful in treatment decisions:

1. Tumor size governs survival in grossly resected SS regardless of all other factors. Moreover, tumor size is linearly associated with the risk of suffering metastatic relapse. Therefore, a granular size classification seems reasonable.

2. A non-risk stratified omission of chemotherapy results in a significant deterioration in outcome.

3. In those patients with tumors <5 cm resected with negative margins, survival is not superior with chemotherapy. Though long-term survival data of those treated without chemotherapy are highly anticipated, omission of chemotherapy seems justified.

4. The survival of patients with tumors < 5 cm resected with positive margins does not differ from those with negative margins.

5. Moreover, no independent factor for suffering local recurrence could be identified.

6. This series is in contrast to many other SS series that identify free margins as crucial factor. However, this is a series where almost all patients have received chemotherapy. The required aggressiveness of local therapy cannot be assessed independently of the systemic therapy administered.

Summarized, patients with grossly resected SS treated according to CWS recommendations have an excellent prognosis. A subgroup probably does not require chemotherapy. Whether size and surgery can serve as criteria for the omission of chemotherapy needs to be tested in prospective preclinical and clinical studies. Biology signature may predict the outcome and may be used for patients’ stratification to better identify patients more appropriate to receive systemic therapy.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00432-021-03614-6.

Acknowledgements We are indebted to the personnel of all participating institutions and thank all patients, parents, and guardians for their willingness to participate in the CWS-trials. We thank Iris Veit-Friedrich, Erika Hallmen, and Simone Feuchtgruber for their excellent data management.

Funding Open Access funding enabled and organized by Projekt DEAL. Supported by the German Childhood Cancer Foundation, Bonn; German Cancer Aid, Bonn; Federal Ministry of Research and Technology, Bonn and the Förderkreis Krebskranke Kinder e.V. Stuttgart, Germany.

Declarations

Conflict of interest We declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Baldi GG et al (2019) Standard treatment and emerging drugs for managing synovial sarcoma: adult’s and pediatric oncologist perspective. Expert Opin Emerg Drugs 24(1):43–53
Bergh P et al (1999) Synovial sarcoma: identification of low and high risk groups. Cancer 85(12):2596–2607
Bianchi G et al (2017) Histology and grading are important prognostic factors in synovial sarcoma. Eur J Surg Oncol 43:1733–1739
Brecht IB et al (2006) Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies. Pediatr Blood Cancer 46(1):11–17
Brodsky JT et al (1992) Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis. Cancer 70(2):484–489
Dantonello TM et al (2008) Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 26(3):406–413
Dantonello TM et al (2009) Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 27(9):1446–1455
Ferrari A et al (1999) Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol 32(1):32–37
Ferrari A et al (2004) Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101(3):627–634
Ferrari A et al (2015) Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol 26(3):567–572
Frustaci S et al (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19(5):1238–1247
Goldblum JR et al (2014) Enzinger and Weiss’s soft tissue tumors, 6th edn. Saunders/Elsevier, Philadelphia
Greenwood M (1926) Reports on public health and medical subjects. The errors of sampling of the survivorship tables. H.M. Stationery Office, London
Guillou L et al (2004) Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22:4040–4050
Harmer M, Denoix P, Hamperl H (1970) The TNM-System. Aktuelle Probleh chir 14:25–36
Hayes-Jordan AA et al (2000) Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable? J Pediatr Surg 35(6):948–953 (discussion 953-4)
Italiano A et al (2009) Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 20(3):425–430
Kaplan EL, Meyer P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Koscielniak E et al (1992) Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer 70(10):2557–2567
Koscielniak E et al (1994) Improved local tumor control by early and risk-adjusted use of radiotherapy in primary non-resectable rhabdomyosarcomas: results of CWS 81 and 86 studies. Klin Padiatr 206(4):269–276
Koscielniak E et al (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17(12):3706–3719
Koscielniak E et al (2013) Report of the CWS-2002-P study: treatment results for soft tissue sarcomas (STS) in childhood and adolescence. Pediatr Blood Cancer 60(53):32
Ladenstein R et al (1993) Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer 71(11):3647–3655
Lewis JJ et al (2000) Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 18(10):2087–2094
Maurer HM et al (1988) The intergroup rhabdomyosarcoma study-I. A final report. Cancer 61(2):209–220
Modritz D et al (2005) Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr 117(5–6):196–209
Okcu MF et al (2001) Synovial sarcoma in children and adolescents: thirty years of experience with multimodal therapy. Med Pediatr Oncol 37(2):90–96
Okcu MF et al (2003) Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 21(8):1602–1611
Orbach D et al (2011) Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group. Pediatr Blood Cancer 57(7):1130–1136
Outani H et al (2019) Favorable outcomes of localized synovial sarcoma patients with a high utilization rate of neoadjuvant and/or adjuvant chemotherapy. Mol Clin Oncol 11(2):151–156
Pappo AS et al (1994) Synovial sarcoma in children and adolescents: the St Jude Children’s Research Hospital experience. J Clin Oncol 12(11):2360–2366
Pizzo PA, Poplack DG (2011) Principles and practice of pediatric oncology, 6th edn. Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia
Riedel RF et al (2018) Systemic anti-cancer therapy in synovial sarcoma: a systematic review. Cancers (basel) 10(11):417
Salcedo-Hernandez RA, Lino-Silva LS, Luna-Ortiz K (2013) Synovial sarcomas of the head and neck: comparative analysis with synovial sarcoma of the extremities. Auris Nasus Larynx 40(5):476–480
Sarcoma Meta-analysis Collaboration (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350(9092):1647–1654
Scheer M et al (2016) Primary metastatic synovial sarcoma: experience of the CWS Study Group. Pediatr Blood Cancer 63(7):1198–1206
Schmidt D et al (1991) Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer 67(6):1667–1672
Spillane AJ et al (2000) Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 18(22):3794–3803
Steegmaier S et al (2017) The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteiltsarkom Studie) trials. Pediatr Blood Cancer 64(1):89–95
Tarkan Y et al (2014) Clinical and pathological features of patients with resected synovial sarcoma: a multicenter retrospective analysis of the Anatolian Society of Medical Oncology. J Cancer Res Ther 10(1):73–78
Trassard M et al (2001) Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 19(2):525–534
Vining CC et al (2017) Adjuvant chemotherapy in resectable synovial sarcoma. J Surg Oncol 116(4):550–558
Yaser S et al (2014) Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients. Med Oncol 31(6):958
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Monika Scheer1 · Christian Vokuhl2 · Sebastian Bauer3 · Jörg Fuchs4 · Steffan Loff5 · Beate Timmermann6 · Marc Münter7 · Anton George Henssen1 · Bernarda Kazanowska8 · Felix Niggli9 · Ruth Ladenstein10 · Gustaf Ljungman11 · Ewa Koscielniak12,13 · Thomas Klingebiel14 on behalf of the European Cooperative Weichteilsarkom Studiengruppe [CWS]

1 Department of Pediatric Hematology and Oncology, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charité–Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
2 Pediatric Pathology, University Hospital of Bonn, Bonn, Germany
3 Sarcoma Center, West German Cancer Center, University of Duisburg-Essen, Essen, Germany
4 Department of Pediatric Surgery and Urology, University Children’s Hospital, Tübingen, Germany
5 Pediatric Surgery, Klinikum Stuttgart, Olgahospital, Stuttgart, Germany
6 Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), West German Cancer Centre (WTZ), West German, University Hospital Essen, Essen, Germany
7 Department of Radiation Oncology, Klinikum Stuttgart, Stuttgart, Germany
8 Department of Pediatric Oncology, University of Wroclaw, Wroclaw, Poland
9 Department of Pediatric Oncology, University of Zurich, Zurich, Switzerland
10 St. Anna Kinderspital and St. Anna Kinderkrebsforschung e.V., Vienna, Austria
11 Pediatric Oncology, Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
12 Klinikum Stuttgart, Olgahospital, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany
13 Department of Pediatric Oncology, University of Tuebingen, Tuebingen, Germany
14 Hospital for Children and Adolescents, Goethe-University Frankfurt (Main), Frankfurt, Germany